Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Cross-over study of the pharmacokinetics of cefonicid administered intravenously or intramuscularly to healthy adult humans

  • 9 Accesses

  • 7 Citations


The pharmacokinetics of cefonicid were investigated in eight healthy adults. A one-gram dose was administered either intramuscularly or intravenously in a cross-over design study. Mean peak cefonicid plasma concentrations of 186 to 204 mcg/ml and 88 to 123 mcg/ml were achieved after intravenous and intramuscular injection, respectively, with elimination half-lives of 4.9 h and 5.3 h. Cefonicid concentrations were measured by both microbiological (M.A.) and high-performance liquid chromatography (HPLC) assays. Results were quite similar with the two techniques, except for the urinary recovery of cefonicid in the first 24 hours (83% of the dose with MA — vs 53% with HPLC method).

The apparent volume of distribution (Vd area) was 0.18 1/kg; the total body clearance (CT) and the renal clearance (CR) were 24–26 ml/min and 15–19 ml/min, respectively. The kinetic data of cefonicid were not significantly different for the two routes of administration.

A one-gram i.v. or i.m. cefonicid dose produced high and prolonged plasma concentrations with a longer half-life than obtained with commonly used cephalosporins.

This is a preview of subscription content, log in to check access.


  1. 1.

    Gomeni R. and Gomeni C. (1978): IGPHARM “interactive graphic Package for Pharmacokinetic Analysis ”. in Computers and Biomedical Research,11, 345–361.

  2. 2.

    Pitkin D., Dubb J., Actor P., Alexander P., Ehrlich S., Familiar R. and Stote R. (1981): Kinetics and renal handling of cefonicid. Clin. Pharmacol. Ther.,30, 587–593.

  3. 3.

    Barrière S.L., Hatheway G.J., Gambertoglio J.G., Lin E.T. and Conte J.E. (1982): Pharmacokinetics of cefonicid, a new broad-spectrum cephalosporin. Antimicrob. Agents Chemother.,21, 935–938.

  4. 4.

    Blair A.D., Maxwell B.H., Forland S.C., Jacob L. and Cutler R.E. (1984): Cefonicid kinetics in subjects with normal and impaired renal function. Clin. Pharmacol. Ther.,35, 798–803.

  5. 5.

    Actor P., Uri J.V., Zajac I., Guarini J.R., Phillips L., Pitkin D.H., Berges D.A., Dunn G.L., Hoover J.R.E. and Weisbach J.A. (1978): SK F 75073, new parenteral broadspectrum cephalosporin with high and prolonged serum levels. Antimicrob. Agents Chemother.,13, 784–790.

  6. 6.

    Mehta R.J., Newman D.J., Bowie B.A., Nash C. H. and Actor P. (1981): Cefonicid, a stable beta-lactamase inhibitor. J. Antibiot. (Tokyo),34, 202–205.

Download references

Author information

Correspondence to J. P. Fillastre.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Fourtillan, J.B., Leroy, A., Lefebvre, M.A. et al. Cross-over study of the pharmacokinetics of cefonicid administered intravenously or intramuscularly to healthy adult humans. European Journal of Drug Metabolism and Pharmacokinetics 10, 225–230 (1985). https://doi.org/10.1007/BF03189746

Download citation


  • Pharmacokinetics
  • Cefonicid
  • Healthy adults